Better Therapeutics, Inc.

NASDAQ
BTTX
paper.types.company
Rentabilité sur six mois: 0%
Rendement en dividendes: 0%
Secteur: Healthcare

0.0001 $

0 $ 0%
0.0001 $
0.0117 $

paper.min_max_per_year

Calendrier des promotions Better Therapeutics, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Better Therapeutics, Inc.

Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2021-10-28
ISIN
US08773T1043
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 0 0
P/BV -35.64 0
P/E 0 0
Efficacité
Nom Signification Grade
ROA -107.6 0
ROE -221.99 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.389 10
Debt/Ratio 0.6507 9
Debt/Equity -26.44 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 523.39 10
Rentabilité EPS, % 217.59 10
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 0.0001 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 0.0001 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.30d 0.0001 $ 0.0001 $ 0.0001 $ 0 % 0 % 0 %
common.calendar.number_days.90d 0.0001 $ 0.0001 $ 0.0001 $ 0 % 0 % 0 %
common.calendar.number_days.180d 0.0001 $ 0.0001 $ 0.0001 $ 0 % 0 % 0 %
common.calendar.number_days.1y 0.0001 $ 0.0001 $ 0.0117 $ 0 % 0 % 0 %
common.calendar.number_days.3y 1.89 $ 0.0001 $ 2.77 $ -99.99 % 0 % 0 %
common.calendar.number_days.5y 0.0001 $ 0.0001 $ 17.14 $ +100 % 0 % 0 %
common.calendar.number_days.10y 0.0001 $ 0.0001 $ 17.14 $ +100 % 0 % 0 %
common.calendar.number_days.ytd 0.0001 $ 0.0001 $ 0.0001 $ 0 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. David P. Perry M.B.A. Co-Founder & Executive Chairman 260k 1968 (57 années)
Mr. Frank L. Karbe CEO, Interim CFO, President & Director 533.37k 1968 (57 années)
Dr. Mark A. Berman M.D. Chief Medical Officer 573.75k 1976 (49 années)
Ms. Kristin Wynholds Chief Product Officer 519.07k 1973 (52 année)
Mr. Andres Camacho Senior VP of Technology & Head of Engineering N/A
Ms. Angela Willis Senior Vice President of Market Access N/A
Leslie Miller Controller N/A
Ms. Jessica Meng Chief Commercial Officer N/A

Informations sur l'entreprise

Adresse: United States, San Francisco. CA, 548 Market Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.bettertx.com